Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy

Journal of Clinical Oncology

Volumn 14, Issue 2, 1996, Pages 503-513

  Perez Soler, R ^a   Fossella, F V ^a   Glisson, B S ^a   Lee, J S ^a   Murphy, W K ^a   Shin, D M ^a   Kemp, B L ^a   Lee, J J ^a   Kane, J ^a   Robinson, R A ^a   Lippman, S M ^a   Kurie, J M ^a   Huber, M H ^a   Raber, M N ^a   Hong, W K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; TOPOTECAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; FEMALE; GRANULOCYTOPENIA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REMISSION; SURVIVAL TIME; THROMBOCYTOPENIA;

EID: 0004484604     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.2.503     Document Type: Article

References (61)

1. Liu LF: DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58:351-375, 1989
2. Slichenmyer WJ, Rowinsky EK, Donehower RC, et al: The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85:271-291, 1993
3. Creemerst GJ, Lund B, Verweij J: Topoisomerase I inhibitors: Topotecan and irinotecan. Cancer Treat Rev 20:73-96, 1994
4. Hertzberg RP, Caranfa MJ, Hecht SM: On the mechanism of topoisomerase I inhibition by camptothecin: Evidence for binding to an enzyme-DNA complex. Biochemistry 28:4629-4638, 1989
5. Hsiang YH, Lihou MG, Liu LF: Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49:5077-5082, 1989
6. Eng WK, McCabe FL, Tan KB, et al: Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. Mol Pharmacol 38:471-480, 1990
7. Tanizawa A, Pommier Y: Topoisomerase I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture. Cancer Res 52:1848-1854, 1992
8. Muggia FM, Creaven PJ, Hansen HS, et al: Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): Correlation with preclinical studies. Cancer Chemother Rep 56:515-521, 1972
9. Jaxel C, Kohn KW, Wani MC, et al: Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: Evidence for a specific receptor site and a relation to antitumor activity. Cancer Res 49:1465-1469, 1989
10. Hertzberg RP, Caranfa MJ, Holden KG, et al: Modification of the hydroxy lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity. J Med Chem 32:715-720, 1989
11. Hsiang Y-H, Liu LF, Wall ME, et al: DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res 49:4385-4389, 1989
12. Tanizawa A, Fujimori A, Fujimori Y, et al: Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 86:836-842, 1994
13. Rowinsky EK, Grochow LB, Hendricks CB, et al: Phase I and pharmacologic study of Topotecan: A novel topoisomerase I inhibitor. J Clin Oncol 10:647-656, 1992
14. Verweij J, Lund B, Beijnen J, et al: Phase I and pharmacokinetics study of Topotecan, a new topoisomerase I inhibitor. Ann Oncol 4:673-678, 1993
15. Wall JG, Burris HA III, Von Hoff DD, et al: A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor Topotecan (SK&K 104864) given as an intravenous bolus every 21 days. Anticancer Drugs 3:337-345, 1992
16. Haas NB, LaCreta FP, Walczak J, et al: Phase I/pharmacokinetic study of Topotecan by 24-hour continuous infusion weekly. Cancer Res 54:1220-1226, 1994
17. Hochster H, Liebes L, Speyer J, et al: Phase I trial of low-dose continuous Topotecan infusion in patients with cancer: An active and well-tolerated regimen. J Clin Oncol 12:553-559, 1994
18. Saltz L, Sirott M, Young C, et al: Phase I clinical and pharmacology study of Topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J Natl Cancer Inst 85:1499-1507, 1993
19. Kudelka A, Edwards C, Freedman B, et al: An open phase II study to evaluate the efficacy and toxicity of Topotecan administered intravenously as 5 daily infusions every 21 days to women with advanced epithelial ovarian carcinoma. Proc Am Soc Clin Oncol 12:1993 (abstr)
20. Schiller JH, Kim K, Johnson D, et al: Phase II study of Topotecan in extensive stage small cell lung cancer. Proc Am Soc Clin Oncol 13:330, 1994 (abstr)
21. Robert F, Wheeler RH, Molthrop DC, et al: Phase II study of Topotecan in advanced head and neck cancer: Identification of an active new agent. Proc Am Soc Clin Oncol 13:281, 1994 (abstr)
22. Kantarjian HM, Beran M, Ellis A, et al: Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood 81:1146-1151, 1993
23. Lynch TJ Jr, Kalish L, Strauss G, et al: Phase II study of Topotecan in metastatic non-small-cell lung cancer. J Clin Oncol 12:347-352, 1994
24. Sugarman SM, Ajani JA, Daugherty K, et al: A Phase II trial of Topotecan (TPT) for the treatment of advanced, measurable colorectal cancer. Proc Am Soc Clin Oncol 13:225, 1994 (abstr)
25. Creemers GJ, Wanders J, Calabresi F, et al: Eighth NCI-EORTC Symposium on New Drugs in Cancer Therapy. Amsterdam, The Netherlands, 1994, p 191
26. Fukuoka M, Niitani H, Suzuki A, et al: A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 10:16-20, 1992
27. Masuda N, Fukuoka M, Kusunoki T, et al: CPT-11: A new derivative of campothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10:1225-1229, 1992
28. Bugat R, Sue E, Rougier P, et al: CPT-11 (irinotecan) as second-line therapy in advanced colorectal cancer (CRC): Preliminary results of multicentric phase II study. Proc Am Soc Clin Oncol 13:200, 1994 (abstr)
29. Pilot HC, Wender D, O'Connell MJ, et al: A phase II trial of CPT-11 (irinotecan) in patients with metastatic colorectal carcinoma: A North Central Cancer Treatment Group (NCCTG) study. Proc Am Soc Clin Oncol 13:197, 1994
30. Rowinsky EK, Grochow LB, Ettinger DS, et al: Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbony-loxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 54:427-436, 1994
31. Ohe Y, Sasaki Y, Shinkai T, et al: Phase I study of pharmacokinetics of CPT-11 with 5-day continuous infusion. J Natl Cancer Inst 84:972-974, 1992
32. Rothenberg ML, Kuhn JG, Burris HA III, et al: Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11:2194-2204, 1993
33. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
34. Hasegawa T, Isobe K, Nakashima I, et al: Higher expression of topoisomerase II in lung cancers than normal lung tissues: Different expression pattern from topoisomerase I. Biochem Biophys Res Commun 195:409-414, 1993
35. Lee JS, Ro JY, Sahin A, et al: Quantitation of proliferating cell fraction (PCF) in non-small cell cancer (NSCLC) using immunostaining for proliferating cell nuclear antigen (PCNA). Proc Am Assoc Cancer Res 31:22, 1990 (abstr)
36. Donnadieu N, Paesmans M, Sculier J-P: Chemotherapy of non-small cell lung cancer according to disease extent: A meta-analysis of the literature. Lung Cancer 7:243-252, 1991
37. Klastersky J, Sculier JP, Bureau G, et al: Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. J Clin Oncol 7:1087-1092, 1989
38. Rosso R, Salvati F, Ardizzoni A, et al: Etoposide versus etoposide plus high-dose cisplatin in the management of advanced non-small cell lung cancer. Cancer 66:130-134, 1990
39. Klastersky J, Sculier JP, Lacroix G, et al: A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer protocol 07861. J Clin Oncol 8:1556-1562, 1990
40. Ruckdeschel JC, Finkelstein DM, Ettinger DS, et al: A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol 4:14-22, 1986
41. Bonomi PD, Finkelstein DM, Ruckdeschel JC, et al: Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: A study of the Eastern Cooperative Oncology Group. J Clin Oncol 7:1602-1613, 1989
42. Abratt RP, Bezwoda WR, Falkson G, et al: Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: A phase II study. J Clin Oncol 12:1535-1540, 1994
43. Anderson H, Lund B, Bach F, et al: Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 12:1821-1826, 1994
44. Fossella FV, Lippman S, Pang A, et al: Phase I/II study of gemcitabine by 30 minute weekly IV m/min × 3 weeks every 4 weeks for non-small cell lung cancer. Proc Am Soc Clin Oncol 12:326, 1993 (abstr)
45. Fukuoka M, Kurita Y, Niitani H: Gemcitabine in non-small cell lung cancer: The Japanese experience, in Efficacy, Symptomatology and Cost as Decision Points in Lung Cancer Treatment: Investigational Experience With Gemcitabine. Seventh World Conference of Lung Cancer Mini-Symposium, Colorado Springs, CO, July 1994
46. Fossella FV, Lee JS, Murphy WK, et al: Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol 12:1238-1244, 1994
47. Fossella FV, Lee JS, Shin DM, et al: Phase II study of docetaxel (Taxotere) for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 13:645-651, 1995
48. Le Chevalier T, Brisgand D, Douillard J-Y, et al: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients. J Clin Oncol 12:360-367, 1994
49. Kawato Y, Aonuma M, Hirota Y, et al: Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51:4187-4191, 1991
50. Niimi S, Nakagawa K, Sugimoto Y, et al: Mechanism of cross-resistance to a camptothecin analogue (CPT-11) in a human ovarian cancer cell line selected by cisplatin. Cancer Res 52:328-333, 1992
51. Grochow LB, Rowinsky EK, Johnson R, et al: Pharmacokinetics and pharmacodynamics of Topotecan in patients with advanced cancer. Drug Metab Dispos 20:706-713, 1992
52. Kaneda N, Yokokura T: Nonlinear pharmacokinetics of CPT-11 in rats. Cancer Res 50:1721-1725, 1990
53. Chen AY, Yu C, Potmesil M, et al: Camptothecin overcomes mdr1-mediated resistance in human Kb carcinoma cells. Cancer Res 51:6039-6044, 1991
54. Hendricks CB, Rowinsky EK, Grochow LB, et al: Effect of P-glycoprotein expression on the accumulation and cytotoxicity of Topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res 52:2268-2278, 1992
55. Houghton PJ, Cheshire PJ, Hallman JC, et al: Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-l-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: Lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethy-lamino-methyl-10-hydroxycamptothecin. Cancer Res 53:2823-2829, 1993
56. Weitz JJ, Jung SH, Marschke RF, et al: Randomized phase II trial of two schedules of Topotecan for the treatment of advanced stage non-small cell lung carcinoma (NSCLC): A North Central Cancer Treatment Group (NCCTG) trial. Proc Am Soc Clin Oncol 14:348, 1995 (abstr)
57. Johnson R, McCabe F, Yu Y: Combination regimens with Topotecan in animal tumor models. Seventh NCI-EORTC Symposium on New Drugs in Cancer Therapy. Amsterdam, The Netherlands, 1992, p 85
58. Rowinsky E, Grochow L, Kaufmann S, et al: Sequence-dependent effects of Topotecan and cisplatin in a phase I and pharmacokinetic study. Proc Am Soc Clin Oncol 13:142, 1994 (abstr)
59. Saltz L, Kanowitz J, Schwartz G, et al: Phase I trial of cisplatin plus Topotecan on a daily × 5 schedule in patients with advanced solid tumors. Proc Am Soc Clin Oncol 14:475, 1995 (abstr)
60. Schaake-Koning C, Van den Bogaert W, Dalesio O, et al: Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 326:524-530,1992
61. Mattern MR, Hofmann GA, McCabe FL, et al: Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor Topotecan (SK&F 104864). Cancer Res 51:5813-5816, 1991